Solstice Advanced Materials Inc. SOLS

Healthcare SIC 2800 - Chemicals & Allied Products NAICS Manufacturing › Chemical Manufacturing derived Nasdaq

Solstice Advanced Materials Inc. ("Solstice," "Solstice Advanced Materials," "we," "us," "our," or the "Company") is a global, differentiated advanced materials company and a leading global provider of refrigerants, blowing agents, conversion services for the nuclear energy sector, semiconductor materials, protective fibers and healthcare packaging. We operate through two segments, reported as Refrigerants & Applied Solutions ("RAS") and Electronic & Specialty Materials ("ESM"). Our business is recognized as an industry innovator as well as a technology and quality leader, supported by some of the industry's most well-known brands.

Our RAS segment is a leading manufacturer of low global warming potential ("LGWP") refrigerants, blowing agents, solvents, and aerosol materials, as well as conversion services for the nuclear energy sector. RAS serves the end markets of cooling, air conditioning and refrigeration ("HVAC/R"), automotive, nuclear energy, building and appliance insulation, and healthcare. RAS products include, among others, LGWP refrigerants, blowing agents, aerosol propellants, cleaning solvents, high-barrier pharmaceutical packaging materials and conversion services for nuclear energy providers. Our products are distributed and sold through well-known brands like Solstice, Genetron, and Aclar. Our ESM segment is a leading provider of electronic materials, high-strength fibers and laboratory life science chemicals. ESM primarily serves the semiconductor, defense, pharmaceutical and construction end markets. ESM products include, among others, sputtering targets, lightweight high-strength fibers and high-purity life science solutions. Our products are distributed and sold through well-known brands like Spectra, Fluka, and Hydranal.

Last close 59.42 2026-10-23
Market cap $9.44B 2026-06-30 share count
52-week range 40.43 - 90.80

Valuation FY2025 figures against the last close

P/S2.4x
P/E39.9x
P/FCF79.3x
EV/EBITDA—
Dividend yield15.9%
Diluted EPS1.49

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • U.S. Plan
  • Europe, Middle East and Africa
  • Other International
Revenue by geography, 3 categories over 3 years. The same figures are in the table below. FY2025 U.S. Plan, FY2025: 2.2B (57.5%) 57% U.S. Plan Europe, Middle East and Africa, FY2025: 922M (23.7%) 24% Europe, Middle East and Africa Other International, FY2025: 730M (18.8%) 19% Other International FY2024 U.S. Plan, FY2024: 2.3B (60.6%) 61% Europe, Middle East and Africa, FY2024: 886M (23.5%) 24% Other International, FY2024: 599M (15.9%) 16% FY2023 U.S. Plan, FY2023: 2.2B (60.4%) 60% Europe, Middle East and Africa, FY2023: 859M (23.5%) 24% Other International, FY2023: 585M (16.0%) 16%
Region FY2025FY2024FY2023
U.S. Plan $2.23B $2.29B $2.21B
Europe, Middle East and Africa $922.0M $886.0M $859.0M
Other International $730.0M $599.0M $585.0M

As the company reported it, from the “Segment Financial Data - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
Revenue $3.89B$3.77B$3.65B—
Cost of revenue $2.64B$2.46B$2.37B—
Gross profit $1.25B$1.31B$1.28B—
R&D $97.0M$83.0M$81.0M—
SG&A $421.0M$392.0M$378.0M—
Interest expense $28.0M$13.0M$16.0M—
Pre-tax income $647.0M$797.0M$814.0M—
Income tax $362.0M$192.0M$195.0M—
Net income $237.0M$594.0M$621.0M—
EPS, basic 1.493.743.91—
EPS, diluted 1.493.743.91—
Shares, diluted (wtd. avg.) 158.9M158.7M158.7M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $534.0M$661.0M$606.0M$549.0M
Receivables $645.0M$569.0M——
Inventory $715.0M$558.0M——
Total current assets $2.39B$1.86B——
Property, plant and equipment $2.06B$1.75B——
Goodwill $820.0M$806.0M$814.0M—
Other intangibles $49.0M$35.0M——
Total assets $5.67B$5.00B——
Accounts payable $909.0M$778.0M——
Short-term debt $4.0M$0——
Total current liabilities $1.71B$1.08B——
Long-term debt $1.97B$0——
Total liabilities $4.30B$1.82B——
Retained earnings $41.0M$0——
Total equity $1.41B$3.26B$3.03B$2.72B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow $455.0M$842.0M$760.0M—
Depreciation and amortisation $24.0M$39.0M$48.0M—
Stock-based compensation $27.0M$17.0M$18.0M—
Capital expenditure $336.0M$296.0M$299.0M—
Investing cash flow -$330.0M-$298.0M-$324.0M—
Financing cash flow -$235.0M-$453.0M-$378.0M—
Dividends paid $1.50B$0$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0002064953-26-000008.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B 4B Revenue, FY2023: 3.6B Gross profit, FY2023: 1.3B Net income, FY2023: 621M Revenue, FY2024: 3.8B Gross profit, FY2024: 1.3B Net income, FY2024: 594M Revenue, FY2025: 3.9B Gross profit, FY2025: 1.2B Net income, FY2025: 237M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — $3.65B $3.77B $3.89B
Gross profit — $1.28B $1.31B $1.25B
Net income — $621.0M $594.0M $237.0M

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed Item 1.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Material agreement signed Item 1.01
  • Other event Item 8.01
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
BCPC BALCHEM CORP $5.64B 37.3x 8.8%
PRM Perimeter Solutions, Inc. $4.55B — 16.4%
IOSP INNOSPEC INC. $2.43B 21.1x -3.7%
NGVT Ingevity Corp $2.39B — -2.7%
CC Chemours Co $1.93B — 0.4%
OLN OLIN Corp $1.78B — 3.7%
HUN Huntsman CORP $1.54B — -5.8%
ECVT Ecovyst Inc. $1.07B — 20.9%